47 results about "Plga nanoparticles" patented technology

The invention belongs to the technical field of biological materials, and particularly relates to nano composite hydrogel as well as a preparation method and application thereof. In the preparation process of the hydrogel, preparation of gelatin hydrazide and preparation of pullulan oxidation are sequentially completed, then preparation of active component loaded PLGA nanoparticles and self-assembly coating with metal-polyphenol are completed, and finally, the metal-polyphenol coated PLGA nanoparticles are mixed with gelatin hydrazide and pullulan oxidation to form gel in situ. The hydrogel has the characteristics of injectability, self-healing, wet adhesion and the like, the metal-polyphenol layer has the effects of resisting inflammation, resisting oxidation and promoting angiogenesis and generates photo-thermal response to near infrared rays, on-demand controllable release of the drug-loaded nanoparticles is achieved, the composite hydrogel can improve the wound surface microenvironment, promote angiogenesis and inhibit inflammation and scar formation, and the drug-loaded nanoparticles can be applied to wound healing. The ointment is suitable for burns, scalds and various complex wounds.

The invention discloses a lipid nanoparticle, a targeted lipid nanoparticle, and a preparation method and application thereof. The lipid nanoparticle has a core-shell structure, the core is formed by PLGA nanoparticles containing drug molecules, and the shell is formed by raw materials including phospholipid, cholesterol and a modification material; wherein the PLGA nanoparticles containing the drug molecules are formed by raw materials comprising PLGA and the drug molecules; the mass ratio of the PLGA to the phospholipid is (1-5): 1; the mass ratio of the phospholipid to the cholesterol is (3-10): 1, and the mass ratio of the phospholipid to the modification material is (3-10): 1; the drug molecules are selected from one or more of insoluble drugs, water-soluble drugs, genes and proteins; and the modification material is PEG-DSPE (Polyethylene Glycol Distearoyl The hardness of the lipid nanoparticles can be regulated and controlled, and cellular uptake can be improved by regulating and controlling the hardness; the targeted lipid nanoparticles can better improve cellular uptake, promote intestinal epithelial cell absorption and improve oral curative effect.

The invention discloses neutral homogeneous lycium barbarum polysaccharide as well as a preparation method and application thereof. Through systematic structure characterization, it is clarified for the first time that the polysaccharide NLBPE1 is atypical arabinogalactan with 1, 5-alpha-L-arabinose as a bridging unit, and the polysaccharide NLBPE1 has a uniform molecular weight and a definite branched chain topological structure. The NLBPE1 serving as an adjuvant and an antigen are jointly entrapped in various delivery systems (such as PLGA nanoparticles, lipidosome, hydrogel and the like) to form the vaccine composition, so that the immunogenicity of the vaccine can be remarkably improved, and the antigen-specific T cell response can be enhanced. The invention provides an application scheme of the polysaccharide as a vaccine adjuvant in tumor immunotherapy and tumor prevention, and particularly shows a remarkable synergistic anticancer effect when the polysaccharide is combined with an immune checkpoint inhibitor for use. The polysaccharide has a clear structure, good biocompatibility and remarkable immunological enhancement activity, and has a wide application prospect of tumor vaccine adjuvants.

The invention provides a POCD treatment medicine composition with dendrobine delivered by a nano-carrier and application, and belongs to the technical field of medicine. The composition consists of dendrobine, a nano-carrier material and a stabilizer, wherein a nano-carrier is PLGA (poly (lactic-co-glycolic acid)) nanoparticles or lipidosome. The particle size of the composition is 50-150nm, the polydispersity index is less than 0.3, and the loading capacity of dendrobine is 5-15%. The invention also provides two preparation methods of the composition. The PLGA nanoparticles are prepared by adopting an emulsification-solvent evaporation method; the liposome is prepared by adopting a film hydration-ultrasonic extrusion method, and each process parameter is specifically limited. The pharmaceutical composition can significantly improve the brain targeting and bioavailability of dendrobine, and can be used for preparing drugs for preventing or treating postoperative cognitive impairment (POCD), and the administration route can be intravenous injection or nasal administration.

The application discloses a kind of Man-PFH-ICG@PLGA nanoparticles and preparation method and application thereof, belong to composite material preparation technical field.The application uses PLGA as carrier, using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs) to mark the surface of it with mannose, and ICG and oxygen-carrying PFH are embedded therein, the obtained Man-PFH-ICG@PLGA nanoparticles have excellent targeting effect on the overexpression of mannose receptor on the surface of tumor cells, significantly promote the effective endocytosis of cells in vitro and tumor enrichment in vivo, directly relieve the hypoxic environment of tumor;It can also supplement oxygen by endogenous, to activate the TRPA1 channel overexpressed on the surface of tumor cells by ROS generated by cells, so as to inhibit cell respiration, reduce oxygen consumption, indirectly relieve the hypoxic environment of tumor, effectively inhibit the growth of tumor cells, and provide a new idea for clinical exploration of antitumor therapy.

The application discloses a kind of Baicalein-loaded mPEG-PLGA nanoparticles based on tumor microenvironment and its preparation method and application.The method is: ultrasonic dispersion preparation Baicalein uniform solution;Then mPEG-PLGA is prepared;Emulsion evaporation method is prepared Baicalein-loaded mPEG-PLGA nanoparticles (PMs-Ba);The nanoparticles can be accumulated in tumor site, improve tumor microenvironment, so as to enhance the sensitivity of breast cancer to chemotherapeutic drugs.The method is simple to operate, provides a new idea for traditional Chinese medicine to be used as adjuvant therapy, and the method has great application potential in early cancer clinical treatment.

The application relates to preparation and application of a giant Eimeria nanosubunit vaccine. The nanosubunit vaccine PLGA-rEmLPL is prepared by coating E. maxima Treg-induced molecule EmLPL recombinant protein (rEmLPL) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmLPL and the nanosubunit vaccine PLGA-rEmLPL are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce good immunoprotective effects on E. maxima infection. After the recombinant protein subunit vaccine rEmLPL is coated with the PLGA nanoparticles, the immunoprotective effect of the nanosubunit vaccine PLGA-rEmLPL on animals is improved compared with that of the subunit vaccine rEmLPL.

The invention discloses a preparation method and application of PLGA (poly (lactic-co-glycolic acid))-curcumin nanoparticles. The invention relates to the technical field of biomedicine, and the preparation method comprises the following steps: taking a polyvinyl alcohol (PVA) aqueous solution as a water phase and a dichloromethane solution of polylactic acid-glycolic acid copolymer (PLGA) and curcumin (Cur) as an oil phase, preparing curcumin-entrapped PLGA nanoparticles (PLGA at Cur NPs) by adopting a water-in-oil-in-water double emulsion method, and the prepared PLGA nanoparticles are spherical, uniform in particle size and uniform in particle size. The carrier PLGA has good biocompatibility and biodegradability and is non-toxic and non-irritant, and a surfactant does not need to be added in the preparation process of the nanoparticles, so that the toxicity is further reduced.

Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.

The invention relates to the technical field of biomedical engineering, and discloses a function-integrated drug-loading end component for an invasive neural electrode, a preparation method and the invasive neural electrode. The end component is integrally formed by a medicine-carrying degradable material through a mold and is configured to bear a puncture structure and a long-term medicine slow-release carrier at the same time. The drug-loaded degradable material comprises a compound system of drug-loaded PLGA nanoparticles and polylactic acid, the polylactic acid serves as a continuous phase to provide mechanical support, and the drug-loaded PLGA nanoparticles serve as a filling phase to provide a slow release function; a gradient pore structure formed by gradient volatilization of a double-solvent system is arranged in the end component; and the end component is induced by an interface solvent to form molecular-level fusion connection with the electrode substrate. The risk that a coating falls off due to interface failure in a traditional separation type design is fundamentally eliminated, collaborative optimization of the puncture performance and the slow release performance is achieved, and the end component is endowed with the multi-stage drug release characteristic matched with the neuroinflammatory reaction stage.

The invention discloses a nano vaccine for treating HPV (human papilloma virus) infection related cervical lesions as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. In order to solve the problem that the response rate of an existing cervical lesion treatment vaccine does not meet clinical requirements, the hybrid membrane with enhanced immunogenicity and improved safety is prepared by applying a membrane fusion technology and combining an autologous tumor cell membrane and an escherichia coli cytoplasmic membrane; meanwhile, PLGA nano particles loaded with HPV16 E5 / E6 / E7 specific CTL epitope long peptide are used as a delivery carrier, and the HM-NPs-LP nano vaccine co-delivering the hybrid membrane and the HPV16 specific antigen peptide is developed. According to the nano vaccine, tumor cells and HPV16 E5 / E6 / E7 specific CTL epitope long peptide are taken as antigens for immunotherapy, dual immune activation of broad spectrum and specific antigens can be realized, personalized multi-effect treatment capacity for HPV infection related cervical diseases is exerted, targeted killing of HPV infection and pathological cells is enhanced, pathological relapse is prevented, and the nano vaccine has good clinical application prospects. And a new strategy is provided for individualized precise immunotherapy.

The present invention relates to a polymer system with a nano-in-micro architecture (fucoidan micromatrix with PLGA nanoparticles incorporated therein) and finds application as a system for controlled delivery of low molecular weight water-soluble medicinal substances (e.g. galantamine hydrobromide, benzydamine hydrochloride, betahistine hydrochloride, etc.). The system includes polylactic-coglycolic acid (PLGA) nanoparticles in a fucoidan matrix, with the PLGA content being from 1% to 10% and fucoidan content being from 90% to 99% in the form of a fucoidan matrix with 100% PLGA nanoparticles incorporated therein, with the microparticles having an average diameter of 2 μm to 10 μm. The polymer system for controlled release of low molecular weight water-soluble drugs, when loaded with low molecular weight water soluble drugs such as galantamine, benzydamine, doxylamine, contains polylactic-co-glycolic acid from 1% to 10% and fucoidan from 90% to 99% in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein, in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein from 94% to 99% and a low molecular weight water-soluble drug from 1% to 6%, wherein the microparticles have an average diameter of 2 μm to 10 μm.

The application discloses a bovine viral diarrhea virus inactivated vaccine containing ginsenoside Rb1 / Rg5-PLGA nanoparticles, and relates to the technical field of biological medicines.The bovine viral diarrhea virus (BVDV) inactivated vaccine comprises inactivated bovine viral diarrhea virus and a vaccine adjuvant; the vaccine adjuvant comprises ginsenoside Rb1 / Rg5-PLGA nanoparticles.The application effectively enhances the application effect of the vaccine by combining the use of PLGA, ginsenoside Rb1 and Rg5, and can cause better humoral immunity and cellular immunity levels, thereby laying a foundation for the development of the BVDV inactivated vaccine for deer.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention discloses a phototherapy nano system for removing candida and lactobacillus, a preparation method of the phototherapy nano system and application of the phototherapy nano system in preparation of drugs for treating vulvovaginal candidiasis. The phototherapy nano system comprises cell membranes with GPIb, GPIIb / IIIa and gC1q-R / P32 receptors; polylactic acid-glycolic acid copolymer (PLGA) nanoparticles wrapped by a cell membrane; a photosensitizer is embedded on the surface of the cell membrane; the preparation method comprises the following steps: extracting cell membrane PM of human platelets; the method comprises the following steps: premixing an IR780 photosensitizer and a cell membrane PM, and embedding IR780 into the cell membrane PM through ultrasonic under a water bath condition to obtain PM (IR); the preparation method comprises the following steps: carrying out water bath ultrasonic treatment on PM (IR) and polylactic acid-glycolic acid copolymer PLGA nanoparticles, and coating the PM (IR) on the polylactic acid-glycolic acid copolymer PLGA nanoparticles to obtain the PM (IR)-NP bionic nanoparticles. The problems of high recurrence rate, drug tolerance and vaginal flora ecological imbalance in the treatment of the recurrent vulvovaginal candidiasis can be relieved.

The application relates to the field of biomaterials and regenerative medicine, in particular to a preparation method and application of fibronectin and collagen protein-loaded PLGA nanoparticles, wherein the preparation method adopts a complex emulsion solvent evaporation method, a buffer solution containing fibronectin, collagen protein and trehalose is used as an inner water phase, a dichloromethane solution of PLGA is used as an oil phase, and a polyvinyl alcohol and trehalose-containing aqueous solution is used as an outer water phase; and the nanoparticles are prepared through emulsification, high-pressure homogenization, dialysis and freeze-drying. The method has the beneficial effects of stable process and effective protection of protein activity. The obtained nanoparticles have uniform particle sizes (100-200 nm), and can realize synergistic controllable release of double proteins. The product organically combines the physical filling support function of PLGA and the biological repair function of active factors, realizes the integration of "filling-regeneration", can significantly reduce the risk of inflammation, and can be safely applied to soft tissue filling, wrinkle improvement and skin wound repair in the field of medical cosmetology.

One of the problems addressed by the present invention is to provide a novel method for capturing a nucleotide chain. The problem is solved by a method for capturing a nucleotide chain from a liquid specimen collected from a subject, the method comprising bringing a liquid specimen into contact with capture probe-bound cationic polymer-modified PLGA nanoparticles and recovering a nucleotide chain from the capture probe-bound cationic polymer-modified PLGA nanoparticles that have been brought into contact with the liquid specimen. The capture probe-bound cationic polymer-modified PLGA nanoparticles each include a nanoparticle core containing PLGA, a coating layer containing a cationic polymer and covering the surface of the core, and a capture probe bound to the coating layer, wherein the capture probe is an oligonucleotide.

The invention relates to the technical field of biomedical engineering, in particular to Pickering emulsion as well as a preparation method and application thereof. According to the invention, lentinan is selected as an immune agonist and is combined with PLGA, so that the immunocompetence of PLGA as an adjuvant is enhanced; the PLGA-coated lentinan can prevent the antigen from being directly exposed in an organic solvent to influence the activity of the antigen; compared with PLGA nanoparticles, the Pickering emulsion has a larger specific surface area and can adsorb more antigens; the Pickering emulsion has good fluidity and can increase the interaction between the PLGA nanoparticles and cell membranes, when the PLGA nanoparticles are in contact with antigen presenting cells (APCs), a large number of antigens are absorbed by the APCs, and the activated APCs can carry a large number of nanoparticles to enter lymph nodes, so that the Pickering emulsion has good lymph node targeting property. Upon uptake of a large number of antigens, the immune cells induce strong cellular or humoral immune responses in various ways.

The invention discloses a probiotic-nano-drug composite microneedle patch as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The probiotic-nano-drug composite microneedle patch is used as a delivery system, so that the probiotics and the drug can be efficiently delivered, the whole body is prevented from being exposed, and the safety is improved; in addition, the PLGA nanoparticles can control slow release of the medicine, so that the utilization rate and the treatment effect of the medicine are remarkably improved; in addition, after the microneedle substrate layer is encapsulated, the activity of probiotics can be maintained, and the local long-acting effect is achieved; when the probiotic-nano-drug composite microneedle patch is used for treating androgenetic alopecia, the androgenetic alopecia is efficiently treated by promoting hair growth, increasing the density and diameter of hair follicles, improving microcirculation and cell proliferation and reducing the expression level of inflammatory factors; therefore, the method has a good application prospect.

The invention discloses an anti-fowl adenovirus veterinary drug composition targeting DDX5 protein and application thereof, and relates to the technical field of antiviral veterinary drugs for fowls, biodegradable polylactic acid-glycolic acid copolymer (PLGA) nanoparticles are used as a core delivery carrier, and siRNA targeting DDX5 protein and a small molecule inhibitor are loaded, so that the anti-fowl adenovirus veterinary drug composition targeting DDX5 protein is prepared, and the anti-fowl adenovirus veterinary drug composition targeting DDX5 protein is prepared. According to the present invention, the dual antiviral effects of gene silencing and protein activity inhibition are achieved, in order to improve the targeting property, the poultry respiratory tract epithelial cell specific ligand is modified on the surface of the PLGA nanoparticle, such that the composition can accurately recognize and gather on the infected site, and the intracellular delivery efficiency is significantly improved; the stability and the long-acting effect of the composition are ensured.

A preparation method for a multifunctional biomimetic delivery platform efficiently crossing mucosal barriers and inducing mucosal immune enhancement and use thereof. The present invention relates to the technical field of biopharmaceuticals. On the basis of a biodegradable PLGA copolymer and a mixed lipid component, mucosal delivery carrier particles capable of simultaneously loading multiple antigens and immunostimulatory components are prepared by means of a double emulsion method, a rotary evaporation coating method, and an ultrasonic method. The PLGA nanoparticles are loading cores. The outer mixed lipid coating can fulfil the functions of mucus penetration, cell uptake, and thus immune activation.

A multi-target DC vaccine based on tumor antigen epitope peptides and its application belong to the field of tumor immunotherapy technology. The vaccine comprises an hr-8 conjugate peptide, an immune adjuvant, a carrier, and an immune memory enhancer. The hr-8 conjugate peptide is a conjugate product formed by chemically linking an hr-8 targeting peptide with at least two different tumor antigen CTL epitope peptides. The immune adjuvant is a combined adjuvant system of the TLR9 agonist CpG ODN and the TLR3 agonist poly(I:C). The carrier is PLGA nanoparticles, and the immune memory enhancer is IL-7 and / or IL-15. This invention utilizes the specific binding of the hr-8 peptide to the DEC-205 receptor on the surface of dendritic cells to achieve efficient synergistic delivery and cross-presentation of multi-target antigens. The combined adjuvant and memory factor significantly enhance CTL activation and promote long-term immune memory formation, giving the multi-target DC vaccine advantages such as strong targeting, broad antigen coverage, and prolonged relapse-free survival.

The invention belongs to the technical field of medicine, and discloses a dressing for treating diabetic foot ulcer, a preparation method and application. The dressing is characterized in that PLGA nanoparticles loaded with deferasirox are fixed on the inner walls of meshes of a silicone mesh stent through a polydopamine adhesion layer; the sodium alginate microspheres encapsulating the WAY 316606 are embedded into the carboxymethyl cellulose matrix, and the surface of the deferasirox-loaded PLGA nanoparticle layer is coated with the sodium alginate microspheres; and after the poloxamer 407 temperature-sensitive hydrogel containing rhPOSTN protein is molded by casting, the poloxamer 407 temperature-sensitive hydrogel containing rhPOSTN protein is coated with the sodium alginate microsphere layer for encapsulating WAY 316606. The thought that skin POSTN + fibroblasts regulate and control diabetic foot skin injury re-healing through iron metabolism regulation and interaction of the skin POSTN + fibroblasts and endothelial cells is proved, a molecular mechanism is disclosed, and a powerful basis is provided for later research.

The invention discloses a herpes zoster vaccine containing a novel adjuvant and a preparation method of the herpes zoster vaccine, and relates to the technical field of vaccines. According to the vaccine, gE protein is used as an antigen, liposome and PLGA nanoparticles are compounded, phospholipid, cholesterol and cholesterol succinic acid monolipid are used for preparing the liposome, the liposome and an antigen solution containing a film-forming agent are mixed and subjected to ultrasonic treatment, then pre-freezing and freeze-drying are conducted, and a resoluble liposome freeze-dried preparation is obtained; the preparation method comprises the following steps: by taking PLGA as a carrier, emulsifying, dialyzing and homogenizing at high pressure to prepare a nano-particle dispersion liquid entrapped with the immunological enhancement factor; and mixing the two components, stabilizing with polyvinyl alcohol, and freeze-drying again to obtain the vaccine preparation. The problems of aggregation, particle size fluctuation and antigen conformation damage caused by easy oxidation instability of a liposome-antigen freeze-drying preparation in freeze-drying, redissolution and storage are solved, and the redissolution stability and consistency are improved through an internal and external synergistic anti-oxidation stable system.

The application belongs to the field of medicine, and discloses an application of POCM-NP@A939572 in preparation of a medicine for treating osteoporosis, wherein the POCM-NP@A939572 comprises osteoclast precursor cell membrane vesicles and NP@A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP@A939572 is PLGA nanoparticles loaded with A939572. The POCM-NP@A939572 obtained by loading the nanoparticles loaded with A939572 small molecule drugs into the osteoclast precursor cell membrane vesicles has an effect of relieving osteoporosis, can inhibit osteoclast differentiation, and can be used for prevention and relief of osteoporosis.

The application provides a supercritical CO2 assisted preparation of quercetin nanoparticles and application thereof to resisting gastric cancer stem cells. The nanoparticles are prepared by encapsulating quercetin with polylactic acid-co-ethylene glycol (PLGA), so as to solve the problems of poor water solubility and low bioavailability of quercetin and improve the inhibiting effect of quercetin on gastric tumor stem cells. Through a specific preparation process, quercetin-PLGA nanoparticles (Qu-PLGA NS) with uniform particle size and uniform dispersion are obtained. Experimental results show that the Qu-PLGA NS can effectively inhibit the growth and proliferation of gastric tumor stem cells, induce apoptosis of the gastric tumor stem cells, and significantly reduce the invasion and metastasis ability of the gastric tumor stem cells. In addition, the nanoparticles can also reverse the multi-drug resistance of the gastric tumor stem cells, improve the curative effect of a chemotherapeutic drug, and reduce side effects. The application provides a new idea and method for the treatment of gastric cancer and has important clinical application value.

The invention relates to the technical field of biomedical materials, and particularly discloses a preparation method of a medicine-containing chitin intravascular stent. The scaffold is prepared from chitin, chitosan, nano-hydroxyapatite, a phosphodiesterase 5 inhibitor loaded on PLGA (poly (lactic-co-glycolic acid)) nanoparticles and the like. The preparation method comprises the following steps: preparing a chitin composite solution, carrying out three-dimensional printing mold forming and gradient freeze drying to obtain a porous scaffold, carrying out ultrasonic-assisted impregnation loading of a drug, and carrying out multiple crosslinking, washing and drying, plasma surface treatment and sterilization packaging to obtain a finished product. The stent can be used for ischemic vascular disease treatment, vascular injury repair and other scenes, and has the core advantages of reliable mechanical support, controllable slow release of drugs and excellent biocompatibility; besides, according to the preparation method, through collaborative design of a multi-step process, integrated regulation and control of the structure and the function are achieved, process parameters are clear, operability is high, the technical scheme is fully disclosed, and industrial application is facilitated.

The invention discloses indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles, and relates to the technical field of nano-drug delivery and skin disease treatment, and the indole-3-lactic acid loaded beta-glucan modified PLGA nanoparticles comprise the following steps: 1, preparing a solution; preparing a solution 1 and a solution 2; 2, emulsifying and forming nano-particles; dropwise adding the solution 2 into the continuously stirred solution 1; adding deionized water while continuously stirring, and carrying out ultrasonic treatment for 10-20 minutes to promote the volatilization of dichloromethane DCM; performing centrifugal washing, removing polyvinylpyrrolidone (PVP) and residual solvent, and performing vacuum drying to obtain polylactic acid-glycolic acid copolymer (PLGA) nanoparticles; step 3, beta-glucan modification: preparing a beta-glucan solution with a concentration of 2 mg / mL according to a mass ratio of 1: 1, and adding a PLGA (at) drug NPs suspension; performing ultrasonic dispersion for 30 minutes and stirring overnight; and carrying out centrifugal washing to remove uncombined beta-glucan, so as to obtain a final product, namely the PLGA (at) drg-beta-glucan nano-particles.

This invention relates to the fields of biomedicine and nanomaterials technology, and provides a bilayer core-shell nanoparticle composite thermosensitive gel for postoperative analgesia, its preparation method, and its applications. The bilayer core-shell nanoparticles comprise: a core of PLGA nanoparticles loaded with magnesium, and a shell of a lipid bilayer loaded with bupivacaine. The composite thermosensitive gel is made by uniformly dispersing the bilayer core-shell nanoparticles in a thermosensitive gel material. By constructing a structure with a lipid shell loaded with bupivacaine and a PLGA core loaded with magnesium, and combining it with a thermosensitive gel, this invention achieves rapid release of bupivacaine for acute postoperative analgesia, and sustained slow release of magnesium ions for long-term anti-inflammatory and repairing effects. This perfectly meets the temporal requirements of postoperative pain management and has broad clinical application prospects.

The application relates to preparation and application of a nano-subunit vaccine for preventing chicken coccidiosis. The nano-subunit vaccine PLGA-rEmTregIM-1 is prepared by coating a giant Eimeria maxima Treg inducing molecule EmTregIM-1 recombinant protein (rEmTregIM-1) with PLGA nanoparticles. The immunoprotective effects of the subunit vaccine rEmTregIM-1 and the nano-subunit vaccine PLGA-rEmTregIM-1 are evaluated through animal immunoprotection tests, and the results show that both the vaccines can produce partial immunoprotections for the giant Eimeria maxima infection. After the recombinant protein subunit vaccine rEmTregIM-1 is coated with the PLGA nanoparticles, the nano-subunit vaccine PLGA-rEmTregIM-1 has an improved immunoprotection effect on animals compared with the subunit vaccine rEmTregIM-1.